The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

This week's dividend activity included increased payouts from Eli Lilly (LLY) and Mastercard (MA) as well as declarations ...

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend ...

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Income investors are naturally drawn to the UK market, where they can find plenty of fat, reliable yields. But diversifying ...

With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

The Global X SuperDividend ETF (SDIV) prioritizes yield above all else, generating a current payout just below 10% that's ...

Eli Lilly (NYSE: LLY) already has seen earnings take off thanks to its weight loss drug portfolio. Tirzepatide, sold as ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.